Cancer cells lose both their energy supply and their backup system
Cancer has long survived our attempts to starve it by simply switching fuels — a metabolic cunning that has frustrated oncology for decades. Researchers in China have now engineered nanoparticles designed to close both escape routes at once, dismantling the glycolytic backup system while simultaneously poisoning the mitochondrial core, achieving tumor inhibition rates as high as 76.6 percent in mouse models. The work, still preclinical, represents a philosophical shift in how we might think about cancer treatment: not as a series of targeted strikes, but as the sealing of an entire metabolic room.
- Cancer's ability to swap energy sources mid-battle has long neutralized therapies that target only one metabolic pathway, rendering even promising copper-based treatments incomplete.
- The newly designed CHNDs nanoparticles attack on two fronts simultaneously — degrading the HK-2 enzyme that opens the glycolytic pathway while releasing copper ions that destroy mitochondria through cuproptosis.
- In laboratory cultures, the combined platform depleted ATP, suppressed glucose consumption, and triggered cascading cellular damage far beyond what either mechanism achieved alone.
- Mouse models showed 55.3% tumor inhibition in breast cancer and 76.6% in colon cancer, with some animals surviving to day 100 compared to a median of 21 days in untreated groups.
- Before human trials can be considered, researchers must resolve critical unknowns: how copper accumulates in the body, how the immune system responds, and whether the approach holds across the genetic diversity of real human tumors.
Cancer cells are metabolically clever — starve them of one energy source and they reach for another. Researchers at Northwestern Polytechnical University set out to eliminate that choice entirely, designing nanoparticles that block both the mitochondrial power supply and the glycolytic backup system at the same time.
The particles, called CHNDs, perform two distinct jobs within a single structure. The first is to degrade hexokinase 2, or HK-2, the enzyme that initiates glycolysis in rapidly dividing tumor cells — not merely inhibiting it, but removing it from the cell altogether. The second is to release copper ions that trigger cuproptosis, a form of cell death driven by mitochondrial damage. The particles are engineered to remain stable in healthy tissue but dissolve in the acidic environment of tumors, releasing both agents in a controlled burst.
In cell cultures, CHNDs outperformed either component alone, reducing glucose consumption, lowering lactate production, depleting ATP, and triggering the protein aggregation that marks cuproptosis. Gene expression analysis revealed disruption across protein degradation, stress response, and energy production pathways simultaneously.
In living animals, the results were substantial. Breast tumor growth was inhibited by 55.3 percent; colon cancer inhibition reached 76.6 percent, with median survival extending from 21 to 29 days and some animals surviving to day 100. The platform also reduced metastatic spread to the lungs.
The conceptual significance lies in treating metabolic flexibility and mitochondrial dependence not as separate problems requiring separate drugs, but as a single integrated vulnerability. Still, the path from mouse to clinic is long. Questions of copper accumulation, immune response, and performance across genetically diverse human tumors must all be answered before this framework can be tested in people.
Cancer cells are metabolically clever. When you starve them of one energy source, they switch to another. Researchers at Northwestern Polytechnical University and their collaborators have been thinking about what happens if you don't give them that option—if you cut off both the mitochondrial power supply and the glycolytic backup system at the same time.
The problem they're addressing is real and specific. Copper-based therapies can kill cancer cells by triggering a process called cuproptosis, which damages the mitochondria where cells normally generate energy. But many tumors don't stay dependent on that single pathway. They're metabolically flexible. When mitochondrial stress hits, they shift their metabolism toward aerobic glycolysis—essentially running on a different fuel source to survive. The therapy works, but the cancer adapts. The new study proposes a way to block both routes simultaneously.
The researchers designed nanoparticles they call CHNDs: copper-based structures decorated with molecules that do two jobs at once. The first job is to degrade hexokinase 2, or HK-2, an enzyme that catalyzes the opening step of glycolysis and is essential to the high metabolic demand of rapidly dividing tumors. Rather than simply inhibiting the enzyme, the platform degrades it—removing it from the cell entirely, which should prevent the tumor from quickly bouncing back to glycolytic metabolism. The second job is to release copper ions that trigger mitochondrial damage and cell death through cuproptosis.
The engineering is intricate. The researchers first built what they call PHDs—degraders that link a molecule targeting HK-2 to a thalidomide derivative that recruits the cellular machinery responsible for protein destruction. In breast cancer and colon cancer cells grown in the lab, these degraders reduced HK-2 expression to roughly 42 to 44 percent of normal levels, measurably impairing glycolytic activity. Then they wrapped this degradation strategy into copper-based metal-organic framework nanoparticles. The particles are designed to remain stable in normal tissue but to break apart in the acidic, chemically rich environment of tumors, releasing both the HK-2 degraders and copper ions in a controlled way.
In cell cultures, the combined approach outperformed either component alone. CHNDs reduced the rate at which cancer cells consumed glucose, lowered lactate production, and depleted ATP—the universal energy currency. At the same time, they increased reactive oxygen species, damaged mitochondrial membranes, and triggered the protein aggregation that characterizes cuproptosis. Gene expression analysis showed widespread disruption across multiple cellular systems: protein degradation pathways, stress responses, mitochondrial assembly, and energy production.
The results in living animals were substantial. In mice bearing orthotopic breast tumors—cancers implanted directly into breast tissue—CHNDs inhibited tumor growth by 55.3 percent. In colon cancer models, the inhibition rate reached 76.6 percent, and median survival extended from 21 days to 29 days, with some animals surviving to day 100. When the researchers examined tumor tissue, they confirmed that HK-2 had been degraded, that the protein aggregation signature of cuproptosis was present, and that tumor cells were dying at elevated rates. In a metastasis model, the nanoplatform also reduced the spread of cancer to the lungs.
What makes this work conceptually important is that it treats two separate cancer vulnerabilities—metabolic flexibility and mitochondrial dependence—as a single integrated problem. Rather than developing two separate drugs and hoping they work together, the researchers built both mechanisms into one nanoplatform. But the work is still preclinical. Before this strategy can move toward human trials, researchers will need to understand how copper accumulates in the body over time, what immune responses the nanoparticles trigger, how the particles behave in the bloodstream, and whether the approach works across the genetic diversity of real tumors. Safety studies in larger animals will be essential. The study provides a framework for how targeted protein degradation and metal-induced cell death can be woven together, but the path from mouse to clinic remains long.
Notable Quotes
The strategy addresses a key limitation of cuproptosis-based cancer therapy: many tumors are metabolically flexible and rely heavily on aerobic glycolysis to survive mitochondrial damage.— Study findings from Northwestern Polytechnical University researchers
The Hearth Conversation Another angle on the story
Why does it matter that you're degrading the enzyme rather than just blocking it?
Because cancer cells are adaptive. If you simply inhibit HK-2, the cell can often upregulate other glycolytic enzymes or find workarounds. Degradation removes the protein entirely from the cell, making compensation much harder.
And the copper component—that's doing something different?
Completely different. Copper triggers cuproptosis, which is mitochondrial damage through protein aggregation and iron-sulfur cluster disruption. It's a distinct cell death pathway. The genius here is that neither pathway alone is enough, but together they close off the two main energy routes a tumor has.
The survival numbers—day 100 in some mice—that's significant?
In a colon cancer model where untreated mice typically die around day 21, having animals survive to day 100 suggests real antitumor activity. But it's still mice. The question is whether this translates to humans, and whether the copper itself causes problems we haven't seen yet.
What's the biggest unknown right now?
Metal accumulation in organs. Copper is essential in small amounts, but these nanoparticles release copper ions directly into tumors and potentially into the bloodstream. We don't know if it builds up in the liver, kidneys, or brain over time, or what that does to healthy tissue.
So this is promising but not ready for patients.
Exactly. It's a proof of concept that the strategy works in principle. But preclinical success and clinical safety are very different things. The next phase is understanding whether this can be given safely to humans.